lundi 20 avril 2015

small molecule AD therapy

No need for dangerous antibodies?

The “overactivity” is a concern because Colton and her team found that microglia immune cells are chewing up an important amino acid, arginine, which could in turn lead to memory loss and build up of the proteins or plaques in the brain associated with the disease. But when it comes to therapies, Colton says people can’t just eat more arginine or take arginine dietary supplements. While arginine could enter the bloodsteam via supplements, it wouldn't necessarily cross over the "blood brain barrier" and enter the brain.

“We have to think about this as a much more complex system than we thought in the past,” she says.

Before the mice began showing Alzheimer’s symptoms, Colton and her team blocked arginase, an enzyme that breaks down arginine, using the drug difluoromethylornithine, also known as DFMO. As a result, the scientists saw fewer microglia and plaques develop in the brains of the mice, and the mice performed better on memory tests.

The results seem promising.....

LRL---are you listening.... anyone???? It echoes echoes echoes


small molecule AD therapy

Aucun commentaire:

Enregistrer un commentaire